Ana Corrionero

This paper introduces kinetic fingerprints to evaluate KIT inhibitors, showing that residence time and dissociation rates predict clinical success and resistance.

The paper analyzes 4,311 protein-small-molecule interactions to show that binding kinetics are mainly controlled by protein dynamics, not ligand structure.

This study develops a covalent LIMK1 inhibitor that selectively targets a unique cysteine, enabling isoform-specific studies of LIMK1 function.

The paper repurposes a benzoxazepinone scaffold originally designed for RIPK1 inhibition to develop a novel type-III LIMK1/2 inhibitor with high selectivity.